These data on the MDSC-mediated function of PVT1 suggest that its overexpression in specific immune cell subsets has the capability of dampening anti-tumor responses and potentially contribute to therapy resistance, especially in the therapeutic settings relying on immune cell reactivation (e.g. immune checkpoints-based regimens, which are largely exploited for combination strategies). The gene discussed is PVT1; the disease is neoplasm.